TRISALUS LIFE SCIENCES, INC.

Communiqués TriSalus Life Sciences, Inc.

Actions

TLSI

US89680M1018

Cours en clôture Nasdaq Autres places de cotation 00:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
7,16 ^USD	-3,76 %		-5,29 %	-15,27 %

30/05	TRISALUS LIFE SCIENCES, INC. : Canaccord Genuity toujours positif	ZM
30/05	TRISALUS LIFE SCIENCES, INC. : Canaccord Genuity à l'achat	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants	24/05	BU
TriSalus Reports Q1 2024 Financial Results and Business Update	15/05	BU
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	07/05	BU
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	06/05	BU
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	30/04	BU
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	01/04	BU
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting	26/03	BU
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting	21/03	BU
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results	11/03	BU
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101	07/03	BU
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors	29/02	BU
TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update	14/11	BU
TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call	07/11	BU
Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications	04/11	BU
TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	03/11	BU
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	25/10/23	BU
TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics	06/09/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT